CN105807054A - 一种子宫内膜癌特异性检测的试剂盒 - Google Patents
一种子宫内膜癌特异性检测的试剂盒 Download PDFInfo
- Publication number
- CN105807054A CN105807054A CN201610361859.4A CN201610361859A CN105807054A CN 105807054 A CN105807054 A CN 105807054A CN 201610361859 A CN201610361859 A CN 201610361859A CN 105807054 A CN105807054 A CN 105807054A
- Authority
- CN
- China
- Prior art keywords
- cypa
- aptamer
- dna
- kit
- endometrial cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种特异检测子宫内膜癌的试剂盒。本发明提供的核酸适体,与人Cyclophilin A蛋白具有较好的亲和能力。利用本发明的核酸适体,可以捕获血液中的Cyclophilin A蛋白,通过其含量的变化来检测子宫内膜癌,将其制备成为相应的试剂盒,将用于子宫内膜癌的筛查。利用本发明的试剂盒,具有高灵敏、成本低的好处。
Description
技术领域
本发明涉及一种用于检测子宫内膜癌的试剂盒及其检测方法。
背景技术
子宫内膜癌作为女性生殖道三大恶性肿瘤之一,占女性生殖道恶性肿瘤的20-30%,在某些欧美国家已居女性生殖道恶性肿瘤首位,严重威胁妇女健康。随着社会发展和人类平均寿命的延长,内膜癌发病率逐年上升并伴有年轻化趋势。子宫内膜癌如果能做到早期诊断,合理治疗,其预后一般较好。子宫内膜癌的主要临床表现为不规则阴道流血,与卵巢癌等其他肿瘤不同,临床诊断主要依靠诊断性刮宫,但哺乳期或浸润型子宫内膜癌的患者,其子宫壁薄弱,刮宫时可能会造成穿孔,给患者造成伤害。
CyclophilinA蛋白(CYPA)又称亲环素A(GeneBankNo.NP_066953),位于胞质及胞核,具有肽酰脯氨酰顺反式异构酶活性,参与蛋白质折叠、装配与运输;在细胞内与环孢素A结合,抑制T细胞活化途径,表现出免疫抑制作用,此外还参与氧化应激诱导及胆固醇代谢过程,并发挥细胞因子的功能。现有技术已经报道,通过检测人亲环素A表达水平来早期诊断子宫内膜癌。因此,检测人亲环素A变得尤为重要。
核酸适体(Aptamer,又称适配体,适配子)是能高亲和性、高特异性的结合某种生物质的单链寡核酸分子(ssDNA或ssRNA)。核酸适体是通过指数富集配体系统进化技术(Systemat1cEvolut1onofL1gandsbyExponent1alenr1chment,SELEX)从人工合成的DNA/RNA文库中筛选得到的能够高度特异性结合靶标分子的单链DNA/RNA。已报道核酸适体的靶标包括金属离子、有机小分子、多肽、蛋白质、细胞甚至组织等。核酸适体的分子识别功能与抗体类似,具有与抗体分子相当甚至更强的靶标识别能力。
发明内容
本发明的目的是提供一种特异结合CYPA的核酸适体及其试剂盒。
本发明提供的核酸适体,是序列表的序列1-14所示的单链DNA。
所述核酸适体与CYPA蛋白具有较好的亲和能力。
还可将所述核酸适体进行修饰或改造,得到所述核酸适体的衍生物。
所述核酸适体的衍生物可为如下任意一种:
a)将所述核酸适体删除部分或增加部分互补的核苷酸,得到的与所述核酸适体具有相同功能的核酸适体的衍生物;
b)将所述核酸适体进行核苷酸取代或部分修饰,得到的与所述核酸适体具有相同功能的核酸适体的衍生物;
c)将所述核酸适体的骨架改造为硫代磷酸酯骨架,得到的与所述核酸适体具有相同功能的核酸适体的衍生物;
d)将核酸适体改造为肽核酸,得到的与所述核酸适体具有相同功能的核酸适体的衍生物;
e)将所述核酸适体连接上荧光、放射性和治疗性物质后,得到的与所述核酸适体具有相同功能的核酸适体的衍生物。
所述核酸适体可用于制备检测CYPA的试剂盒。
利用本发明的核酸适体,可以捕获中唾液中的中的CYPA,从而用于相关子宫内膜癌筛查。利用本发明的核酸适体,具有高灵敏、成本低、易制备、易保存的优点。本发明具有很高的应用价值。
具体实施方式
以下的实施例便于更好地理解本发明,但并不限定本发明。下述实施例中的实验方法,如无特殊说明,均为常规方法。
实施例1CYPA蛋白的获得
将Genbank:NP_066953所示的CYPA基因通过本领域常规的真核表达方式进行表达,获得了相应的目的多肽蛋白。
实施例2核酸适体的筛选和制备
设计两端包含大约20个核苷酸、中间包括个核苷酸的随机核酸文库如下:
5‘-ATCGTCACCATGGATACATG(N39)TTGCACAATTGGACAGTTAC-3’;N39代表39个随机核苷酸。
将单链DNA文库扩增为双链DNA,产物经2%琼脂糖凝胶电泳并切胶回收纯化;以回收的双链DNA为模板,体外转录出单链RNA随机文库,转录产物经PAGE纯化。75μgRNA文库经硝酸纤维素膜反筛去除与膜结合的RNA分子,然后与2ugCYPA蛋白,37℃孵育30min,反应液经硝酸纤维素膜滤过,洗涤滤膜;然后将滤膜剪碎,置于洗脱缓冲液(6mol/L尿素,0.55mol/L醋酸铵,l.5mmol/LEDTA,0.15%SDS)中煮沸5min,离心,取上清,无水乙醇沉淀RNA,并重新溶解于20μ1DEPC水中;以RNA为模板RT-PCR扩增双链DNA,体外转录出RNA文库用于下一轮筛选;每轮筛选过程中RT-PCR得到双链DNA文库,以该双链DNA为模板体外转录出RNA适配子库,筛选共进行11轮。得到了14个适配子,其序列分别为SEQIDNO:1-14所示。具体序列如下所示:
CYPA-1:ATCGTCACCATGGATACATGACTTAACCACGCTCCATTCTATCAATTAACCCGCACTAATTGCACAATTGGACAGTTAC
CYPA-2:ATCGTCACCATGGATACATGATATATTAACCCTCACTAATCTCCTCATCCTACTATAAGTTGCACAATTGGACAGTTAC
CYPA-3:ATCGTCACCATGGATACATGCACTATATTCACGCTAAACCTTTCTTCCTCGCATACCTATTGCACAATTGGACAGTTAC
CYPA-4:ATCGTCACCATGGATACATGCTATTCCCTTTCCGCTACAATCCAATAATCACGCAACACTTGCACAATTGGACAGTTAC
CYPA-5:ATCGTCACCATGGATACATGTTATTCCTGTCTTCACACCGACTTCACATATATCTTCAATTGCACAATTGGACAGTTAC
CYPA-6:ATCGTCACCATGGATACATGCTACCGCTTCCACTCTCCTTATCCATCTTACATTCCCTCTTGCACAATTGGACAGTTAC
CYPA-7:ATCGTCACCATGGATACATGCATACTACAAACCTCCTATAATCTGTTATCAACACTAATTTGCACAATTGGACAGTTAC
CYPA-8:ATCGTCACCATGGATACATGTATTTTCTTCCACTCCCATACTTAGAATAAGAATCCACTTTGCACAATTGGACAGTTAC
CYPA-9:ATCGTCACCATGGATACATGTATGACAATTATTGCCCACTAGATACTTCCACGCAAATCTTGCACAATTGGACAGTTAC
CYPA-10:ATCGTCACCATGGATACATGACTTATCATATCCACCTTATCACATCATCCCCACTTCCTTTGCACAATTGGACAGTTAC
CYPA-11:ATCGTCACCATGGATACATGTCGTTCTCACGAATTCACACACTAACTCCCACACATACATTGCACAATTGGACAGTTAC
CYPA-12:ATCGTCACCATGGATACATGCACTATATCTTACTATCATTTAATCCTTTCACTCCCAACTTGCACAATTGGACAGTTAC
CYPA-13:ATCGTCACCATGGATACATGTCACTCCGCCGCACCACTAATTCACGCTAAACTTATCTTTTGCACAATTGGACAGTTAC
CYPA-14:ATCGTCACCATGGATACATGATTCTCTCCGAACTTCTACATATAAAACCAAGAATTCTTTTGCACAATTGGACAGTTAC
实施例3蛋白结合适配子的性能测定
将适配子分别取2.0μg,用牛小肠碱性磷酸酶(CIP)37℃消化lh,纯化回收去磷酸化的RNA;通过T4多核苷酸激酶标记[γ-32P]ATP于去磷酸化的RNA分子末端。10nmol放射性标记的适配子分别与不同浓度(1-200nM)的CYPA37℃孵育30min,各组反应液经硝酸纤维素膜滤过,洗涤滤膜,干燥滤膜,液闪计数仪测定滤膜上残留的放射量,同一样品平行做两次测定。计算各个适配子与目的蛋白的解离常数。结果如下:
名称 | 解离常数Kd(单位nM) |
CYPA-1 | 11.3 |
CYPA-2 | 12.5 |
CYPA-3 | 13.0 |
CYPA-4 | 12.8 |
CYPA-5 | 12.7 |
CYPA-6 | 11.9 |
CYPA-7 | 11.4 |
CYPA-8 | 12.4 |
CYPA-9 | 12.7 |
CYPA-10 | 12.0 |
CYPA-11 | 13.1 |
CYPA-12 | 13.0 |
CYPA-13 | 12.6 |
CYPA-14 | 12.8 |
PBS空白对照 | 无结合能力 |
实施例4所述适配子特异性分析以及稳定性分析
分别采用人血白蛋白,免疫血清球蛋白,pg120蛋白,大肠杆菌外膜蛋白A,COCH蛋白,CYPA蛋白,与14条适配子进行特异性检测,经过结合试验发现,这些适配子都不与这些蛋白相结合,而只与CYPA蛋白结合保持较高的特异性。
将所述的适配子,取0.2ug,分别置于常温的血清、水溶液中,放置二周。通过RT-PCR检测,发现三周的放置其结构稳定,没有被降解。
实施例5所述适配子疾病的诊断
取8个子宫内膜癌患者和4个正常人的血液,使用生理盐水稀释,获得目标样本。
将14个偶联有标记的适配子分别与8个患者以及4个正常人的分泌物混合30min,通过生物素分离,定量分析其中的CYPA蛋白的含量,通过分析发现,8个子宫内膜癌患者中CYPA蛋白的含量显著增加,超过了规定的阈值。达到了子宫内膜癌的诊断标准。由此可见,其诊断效果较好。
以上仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,凡在本发明的精神和原则之内所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
序列表
〈110〉李静
〈120〉一种子宫内膜癌特异性检测的试剂盒
〈160〉14
〈210〉1
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-1
ATCGTCACCATGGATACATGACTTAACCACGCTCCATTCTATCAATTAACCCGCACTAATTGCACAATTGGACAGTTAC
〈210〉2
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-2
ATCGTCACCATGGATACATGATATATTAACCCTCACTAATCTCCTCATCCTACTATAAGTTGCACAATTGGACAGTTAC
〈210〉3
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-3
ATCGTCACCATGGATACATGCACTATATTCACGCTAAACCTTTCTTCCTCGCATACCTATTGCACAATTGGACAGTTAC
〈210〉4
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-4
ATCGTCACCATGGATACATGCTATTCCCTTTCCGCTACAATCCAATAATCACGCAACACTTGCACAATTGGACAGTTAC
〈210〉5
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-5
ATCGTCACCATGGATACATGTTATTCCTGTCTTCACACCGACTTCACATATATCTTCAATTGCACAATTGGACAGTTAC
〈210〉6
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-6
ATCGTCACCATGGATACATGCTACCGCTTCCACTCTCCTTATCCATCTTACATTCCCTCTTGCACAATTGGACAGTTAC
〈210〉7
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-7
ATCGTCACCATGGATACATGCATACTACAAACCTCCTATAATCTGTTATCAACACTAATTTGCACAATTGGACAGTTAC
〈210〉8
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-8
ATCGTCACCATGGATACATGTATTTTCTTCCACTCCCATACTTAGAATAAGAATCCACTTTGCACAATTGGACAGTTAC
〈210〉9
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-9
ATCGTCACCATGGATACATGTATGACAATTATTGCCCACTAGATACTTCCACGCAAATCTTGCACAATTGGACAGTTAC
〈210〉10
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-10
ATCGTCACCATGGATACATGACTTATCATATCCACCTTATCACATCATCCCCACTTCCTTTGCACAATTGGACAGTTAC
〈210〉11
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-11
ATCGTCACCATGGATACATGTCGTTCTCACGAATTCACACACTAACTCCCACACATACATTGCACAATTGGACAGTTAC
〈210〉12
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-12
ATCGTCACCATGGATACATGCACTATATCTTACTATCATTTAATCCTTTCACTCCCAACTTGCACAATTGGACAGTTAC
〈210〉13
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-13
ATCGTCACCATGGATACATGTCACTCCGCCGCACCACTAATTCACGCTAAACTTATCTTTTGCACAATTGGACAGTTAC
〈210〉14
〈211〉79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-14
ATCGTCACCATGGATACATGATTCTCTCCGAACTTCTACATATAAAACCAAGAATTCTTTTGCACAATTGGACAGTTAC
Claims (3)
1.一种用于子宫内膜癌检测的试剂盒,其含有能特异性与CYPA蛋白特异性结合的核酸适体。
2.如权利要求1所述的试剂盒,其特征在于:所述核酸适体的序列如SEQIDNo:12所述。
3.一种检测子宫内膜癌的方法,其特征在于利用权利要求1所述的试剂盒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610361859.4A CN105807054A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510807002.6A CN105223358B (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361859.4A CN105807054A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510807002.6A Division CN105223358B (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105807054A true CN105807054A (zh) | 2016-07-27 |
Family
ID=54992426
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510807002.6A Active CN105223358B (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610370066.9A Pending CN105842445A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610369946.4A Pending CN105866412A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361857.5A Pending CN105807068A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361858.XA Pending CN105954516A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361917.3A Pending CN105842444A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361859.4A Pending CN105807054A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610370068.8A Pending CN105842446A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361860.7A Pending CN105866411A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361916.9A Pending CN105807069A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510807002.6A Active CN105223358B (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610370066.9A Pending CN105842445A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610369946.4A Pending CN105866412A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361857.5A Pending CN105807068A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361858.XA Pending CN105954516A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361917.3A Pending CN105842444A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610370068.8A Pending CN105842446A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361860.7A Pending CN105866411A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
CN201610361916.9A Pending CN105807069A (zh) | 2015-11-22 | 2015-11-22 | 一种子宫内膜癌特异性检测的试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (10) | CN105223358B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105886659A (zh) * | 2016-06-29 | 2016-08-24 | 北京泱深生物信息技术有限公司 | Dstn基因及其表达产物作为子宫内膜癌的诊治靶标 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101261279A (zh) * | 2008-04-11 | 2008-09-10 | 四川大学 | 子宫内膜癌诊断试剂、试剂盒及防治药物 |
US20130078645A1 (en) * | 2010-01-29 | 2013-03-28 | Psynova Neurotech Ltd. | Biomarkers |
CN104109667A (zh) * | 2014-06-24 | 2014-10-22 | 叶尚勉 | 一种核酸片段及其用途 |
CN104830867A (zh) * | 2015-06-07 | 2015-08-12 | 杨洋 | 一种能够特异性结合癌细胞中的dkk1蛋白的适配子 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451609B1 (en) * | 1996-05-30 | 2002-09-17 | The Cleveland Clinic Foundation | Method of detecting gynecological carcinomas |
US6591144B2 (en) * | 2001-10-23 | 2003-07-08 | The Administrators Of The Tulane Educational Fund | Steerable catheter and method for locating coronary sinus |
AU2014209218B2 (en) * | 2013-01-25 | 2018-06-07 | Xcell Biosciences, Inc. | Methods, compositions, kits, and systems for selective enrichment of target cells |
-
2015
- 2015-11-22 CN CN201510807002.6A patent/CN105223358B/zh active Active
- 2015-11-22 CN CN201610370066.9A patent/CN105842445A/zh active Pending
- 2015-11-22 CN CN201610369946.4A patent/CN105866412A/zh active Pending
- 2015-11-22 CN CN201610361857.5A patent/CN105807068A/zh active Pending
- 2015-11-22 CN CN201610361858.XA patent/CN105954516A/zh active Pending
- 2015-11-22 CN CN201610361917.3A patent/CN105842444A/zh active Pending
- 2015-11-22 CN CN201610361859.4A patent/CN105807054A/zh active Pending
- 2015-11-22 CN CN201610370068.8A patent/CN105842446A/zh active Pending
- 2015-11-22 CN CN201610361860.7A patent/CN105866411A/zh active Pending
- 2015-11-22 CN CN201610361916.9A patent/CN105807069A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101261279A (zh) * | 2008-04-11 | 2008-09-10 | 四川大学 | 子宫内膜癌诊断试剂、试剂盒及防治药物 |
US20130078645A1 (en) * | 2010-01-29 | 2013-03-28 | Psynova Neurotech Ltd. | Biomarkers |
CN104109667A (zh) * | 2014-06-24 | 2014-10-22 | 叶尚勉 | 一种核酸片段及其用途 |
CN104830867A (zh) * | 2015-06-07 | 2015-08-12 | 杨洋 | 一种能够特异性结合癌细胞中的dkk1蛋白的适配子 |
Also Published As
Publication number | Publication date |
---|---|
CN105866412A (zh) | 2016-08-17 |
CN105223358B (zh) | 2016-09-14 |
CN105807068A (zh) | 2016-07-27 |
CN105842445A (zh) | 2016-08-10 |
CN105842444A (zh) | 2016-08-10 |
CN105954516A (zh) | 2016-09-21 |
CN105223358A (zh) | 2016-01-06 |
CN105842446A (zh) | 2016-08-10 |
CN105807069A (zh) | 2016-07-27 |
CN105866411A (zh) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105223358B (zh) | 一种子宫内膜癌特异性检测的试剂盒 | |
CN105203763B (zh) | 一种口腔癌特异性检测的试剂盒 | |
CN106093434A (zh) | 一种用于肝癌检测的试剂盒 | |
CN105785007A (zh) | 一种子宫内膜癌特异性检测的试剂盒 | |
CN105823894A (zh) | 一种子宫内膜癌特异性检测的试剂盒 | |
CN105823879A (zh) | 一种子宫内膜癌特异性检测的试剂盒 | |
CN105823895A (zh) | 一种子宫内膜癌特异性检测的试剂盒 | |
CN105319376B (zh) | 一种用于检测鼻咽癌的试剂盒及其检测方法 | |
CN105334327A (zh) | 一种用于检测眼病的试剂盒及其检测方法 | |
CN105353126B (zh) | 一种唇癌特异性检测的试剂盒 | |
CN105334328A (zh) | 一种用于检测眼科疾病的试剂盒及其检测方法 | |
CN105177013A (zh) | 一种用于检测脑血管疾病的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160727 |